Both semaglutide and tirzepatide reduce insulin resistance and improve insulin sensitivity, critical for patients managing excess weight, blood sugar, and metabolic-associated liver disease
Retatrutide, a new weight loss drug from Eli Lilly, shows promising results in clinical trials, but its not yet available
Flow Wellness reviews any concentration changes with patients to ensure safe and accurate administration
This feature facilitates timely intervention and personalized support when needed, promoting compliance and a sense of accountability for patients
Special Considerations Another important factor is how these medications impact appetite
A program with quarterly follow-ups at $50 each adds $16/month to the effective cost